Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.
Lee KW, Mahalingam D, Shim BY, Kim IH, Oh DY, Uronis H, Sym SJ, Sonbol M, Almhanna K, Tejani MA, Kang B, Kagey MH, Stilian M, Jia C, Sirard CA, Altura R, Ajani JA, Klempner SJ.
Lee KW, et al.
Nat Commun. 2026 Feb 6;17(1):1437. doi: 10.1038/s41467-026-69394-0.
Nat Commun. 2026.
PMID: 41651836
No abstract available.